News - Oncology, Gastro-intestinals


Popular Filters

Roche highlights late-stage pipeline beyond cancer


Swiss drug major Roche has provided an update from its leading late-stage pipeline comprising 10 new…


Helsinn and Zealand to advance elsiglutide for chemotherapy-induced diarrhea prevention


Privately-held Swiss pharmaceutical group Helsinn and its partner, Denmark-based Zealand Pharma A/S (Nasdaq:…

elsiglutideGastro-intestinalsHelsinnOncologyPharmaceuticalResearchZealand Pharma

Lexicon Pharma updates on clinical pipeline


US drug developer Lexicon Pharmaceutical (Nasdaq: LXRX) yesterday updated its drug development pipeline,…

BiotechnologyDiabetesGastro-intestinalsLexicon PharmaceuticalsLX1032LX1033LX4211OncologyResearchtelotristat etiprate

Positive Ph III results for AbbVie's Humira in pediatric Crohn's disease; five leukemia studies suspended


AbbVie (NYSE: ABBV), the new spin-out from Abbott Laboratories, has announced the first long-term, patient-reported…

Abbott LaboratoriesAbbVieAnti-Arthritics/RheumaticsGastro-intestinalsHumiraOncologyPharmaceuticalResearch

Pfizer links with SFJ Pharma for dacomitinib trial; settles with Mylan


SFJ Pharmaceuticals Group, a global drug development group of companies which provides a unique co-development…

dacomitinibDetrol LAGastro-intestinalsGenericsLegalMylan LaboratoriesNorth AmericaOncologyPatentsPfizerPharmaceuticalResearchSFJ Pharmaceuticals

AB Science leaps as GIST candidate masitinib beats Sutent


France-based AB Science (AB: EN Paris) saw its share price rocket as much as 72% to 10.60 euros after…

AB ScienceGastro-intestinalsmasitinibOncologyPfizerPharmaceuticalResearchSutent

Back to top